Try our Advanced Search for more refined results

Ziegler v. GW Pharmaceuticals, PLC et al

  1. March 21, 2023

    GW Pharma Investors Ink $7.75M Deal In Suit Over Jazz Sale

    GW Pharmaceuticals investors urged a California federal judge on Monday to grant preliminary approval to a $7.75 million settlement that ends their claims the British company misled shareholders to push through its $7.2 billion sale to Ireland-based Jazz Pharmaceuticals, calling it an "excellent" result.

  2. June 06, 2022

    GW Pharma Wants Judge To Nix Investor Suit Over $7.2B Deal

    GW Pharmaceuticals has asked a California federal judge to toss a proposed securities class action alleging the company misled investors to achieve a $7.2 billion acquisition deal, arguing that the purportedly misleading statements at issue were forward-looking and protected by cautionary language.

  3. January 19, 2022

    2 Firms Will Lead Investor Suit Over GW Pharma's $7.2B Deal

    A California federal judge has appointed Monteverde & Associates and Kahn Swick & Foti as co-lead counsel of a proposed securities class action against GW Pharmaceuticals over claims that it misled investors to achieve a $7.2 billion acquisition deal with Ireland-based Jazz Pharmaceuticals.

  4. August 04, 2021

    2 Firms Seek To Lead GW Pharma Suit Over $7.2B Deal

    Monteverde & Associates and Kahn Swick & Foti have asked a California federal judge to appoint them co-lead counsel of a proposed securities class action against GW Pharmaceuticals over claims that the cannabinoid-derived treatment manufacturer misled investors to achieve a $7.2 billion acquisition deal with Ireland-based Jazz Pharmaceuticals.